Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5783719, 6 pages
https://doi.org/10.1155/2017/5783719
Research Article

CYP2C192 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls

1Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco, Chile
2Department of Internal Medicine, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile
3Facultad de Medicina, Universidad de Concepción, Concepción, Chile

Correspondence should be addressed to Luis A. Salazar; lc.aretnorfu@razalas.siul

Received 1 March 2017; Accepted 6 June 2017; Published 13 July 2017

Academic Editor: Stelvio M. Bandiera

Copyright © 2017 Jenny Ruedlinger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Fintel, “Antiplatelet therapy in cerebrovascular disease: implications of the management of artherothrombosis with clopidogrel in high-risk patients and the clopidogrel for high artherothrombotic risk and ischemic stabilization, management, and avoidance studies' results for cardiologists,” Clinical Cardiology, vol. 30, no. 12, pp. 604–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Rai, R. L. Seip, A. Gupta et al., “CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance,” Connecticut Medicine, vol. 76, no. 5, pp. 267–272, 2012. View at Google Scholar · View at Scopus
  3. S. R. Mehta, S. Yusuf, R. J. G. Peters et al., “Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” The Lancet, vol. 358, no. 9281, pp. 527–533, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Takahashi, T. Saito, M. Ito et al., “Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation,” Pharmacogenomics Journal, vol. 15, no. 1, pp. 26–32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Ferri, A. Corsini, and S. Bellosta, “Pharmacology of the new P2Y12 receptor inhibitors: Insights on pharmacokinetic and pharmacodynamic properties,” Drugs, vol. 73, no. 15, pp. 1681–1709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Harmsze, J. W. Van Werkum, H. J. Bouman et al., “Besides CYP2C19∗2, the variant allele CYP2C9∗3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation,” Pharmacogenetics and Genomics, vol. 20, no. 1, pp. 18–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. E. Viveros, C. Areán, S. Gutiérrez et al., “Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients,” Archivos de Cardiologia de Mexico, vol. 86, no. 4, pp. 297–304, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. W.-Y. Zhu, T. Zhao, X.-Y. Xiong et al., “Association of CYP2C19 polymorphisms with the clinical efficacy of clopidogrel therapy in patients undergoing carotid artery stenting in Asia,” Scientific Reports, vol. 6, Article ID 25478, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Grosdidier, J. Quilici, M. Loosveld et al., “Effect of CYP2C19∗2 and ∗17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications,” American Journal of Cardiology, vol. 111, no. 7, pp. 985–990, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-H. Jeong, U. S. Tantry, I.-S. Kim et al., “Effect of CYP2C19∗2 and ∗23 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin,” Circulation: Cardiovascular Interventions, vol. 4, no. 6, pp. 585–594, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Frére, T. Cuisset, B. Gaborit, M.-C. Alessi, and J.-S. Hulot, “The CYP2C19∗17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome,” Journal of Thrombosis and Haemostasis, vol. 7, no. 8, pp. 1409–1411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. A. Tiroch, D. Sibbing, W. Koch et al., “Protective effect of the CYP2C19∗17 polymorphism with increased activation of clopidogrel on cardiovascular events,” American Heart Journal, vol. 160, no. 3, pp. 506–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Pedersen, F. Nielsen, T. B. Stage et al., “CYP2C19∗17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel,” Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 11, pp. 870–878, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Wilson, J. Brittenden, P. Bachoo, I. Ford, and G. F. Nixon, “Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty,” Journal of Vascular Surgery, vol. 50, no. 4, pp. 861–869, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Johansen, M. Brekke, I. Seljeflot, A. G. Semb, and H. Arnesen, “Blood platelet count and reactivity are associated with restenosis 6 months after coronary angioplasty,” Scandinavian Cardiovascular Journal, vol. 38, no. 4, pp. 211–215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. G. K. Owens, M. S. Kumar, and B. R. Wamhoff, “Molecular regulation of vascular smooth muscle cell differentiation in development and disease,” Physiological Reviews, vol. 84, no. 3, pp. 767–801, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S. A. Scott, K. Sangkuhl, C. M. Stein et al., “Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update,” Clinical Pharmacology and Therapeutics, vol. 94, no. 3, pp. 317–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. Salazar, C. E. Melo, S. A. Cavalli, H. M. Hinuy, M. H. Hirata, and R. D. Hirata, “Micrométodo para extração de DNA genômico útil no diagnóstico molecular da hipercolesterolemia familial,” Revista Brasileira de Análises Clínicas, vol. 33, article 6, 2001. View at Google Scholar
  19. Á. Roco, L. Quiñones, J. A. G. Agúndez et al., “Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations,” Frontiers in Genetics, vol. 3, Article ID Article 229, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. V. Bravo-Villalta, K. Yamamoto, K. Nakamura, A. Bayá, Y. Okada, and R. Horiuchi, “Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study,” European Journal of Clinical Pharmacology, vol. 61, no. 3, pp. 179–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Isaza, J. Henao, J. H. Isaza Martínez, J. C. Sepúlveda Arias, and L. Beltrán, “Phenotype-genotype analysis of CYP2C19 in Colombian mestizo nidividuals,” BMC Clinical Pharmacology, vol. 7, article no. 6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-R. Luo, R. E. Poland, K.-M. Lin, and Y.-J. Y. Wan, “Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study,” Clinical Pharmacology and Therapeutics, vol. 80, no. 1, pp. 33–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. P. Nowak, E. M. Sellers, and R. F. Tyndale, “Canadian Native Indians exhibit unique CTP2A6 and CTP2C19 mutant allele frequencies,” Clinical Pharmacology and Therapeutics, vol. 64, no. 4, pp. 378–383, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. S. I. Hamdy, M. Hiratsuka, K. Narahara et al., “Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population,” British Journal of Clinical Pharmacology, vol. 53, no. 6, pp. 596–603, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Bathum, E. Skjelbo, T. K. Mutabingwa, H. Madsen, M. Hørder, and K. Brøsen, “Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population,” British Journal of Clinical Pharmacology, vol. 48, no. 3, pp. 395–401, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Khedhaier, E. Hassen, N. Bouaouina, S. Gabbouj, S. B. Ahmed, and L. Chouchane, “Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma,” BMC Cancer, vol. 8, article no. 109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Allabi, J.-L. Gala, J.-P. Desager, M. Heusterspreute, and Y. Horsmans, “Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations,” British Journal of Clinical Pharmacology, vol. 56, no. 6, pp. 653–657, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Namazi, N. Azarpira, F. Hendijani, M. B. Khorshid, G. Vessal, and A. R. Mehdipour, “The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran,” Clinical Therapeutics, vol. 32, no. 6, pp. 1050–1060, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Nassar, O. Amro, H. Abu-Rmaileh, I. Alshaer, M. Korachi, and S. Ayesh, “ABCB1 C3435T and CYP2C19∗2 polymorphisms in a Palestinian and Turkish population: a pharmacogenetic perspective to clopidogrel,” Meta Gene, vol. 2, no. 1, pp. 314–319, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Schulz, D. Sibbing, S. Braun et al., “Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents,” American Heart Journal, vol. 160, no. 2, pp. 355–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Oikawa, J. Yajima, M. A. Costa et al., “Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential ‘thromborestenosis’ phenomenon,” EuroIntervention, vol. 6, no. 3, pp. 380–387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Nishio, T. Shinke, H. Otake et al., “Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel,” Circulation Journal, vol. 76, no. 10, pp. 2348–2355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Sawada, T. Shinke, J. Shite et al., “Impact of cytochrome P450 2C19∗2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel,” Circulation Journal, vol. 75, no. 1, pp. 99–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Nozari, S. Vosooghi, M. Boroumand et al., “The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: a case-match study,” The Anatolian Journal of Cardiology, vol. 15, no. 5, pp. 348–353, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. Shin, J. Kwon, A.-R. Park et al., “Association of CYP2C19∗2 and ∗3 genetic variants with essential hypertension in Koreans,” Yonsei Medical Journal, vol. 53, no. 6, pp. 1113–1119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. Y.-J. Lin, J.-W. Li, M.-J. Zhang et al., “The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment,” CNS Neuroscience and Therapeutics, vol. 20, no. 2, pp. 125–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Elezi, A. Kastrati, J. Pache et al., “Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement,” Journal of the American College of Cardiology, vol. 32, no. 7, pp. 1866–1873, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Kastrati, A. Schömig, S. Elezi et al., “Predictive factors of restenosis after coronary stent placement,” Journal of the American College of Cardiology, vol. 30, no. 6, pp. 1428–1436, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Ritsinger, N. Saleh, B. Lagerqvist, and A. Norhammar, “High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus,” Circulation: Cardiovascular Interventions, vol. 8, no. 6, Article ID e002328, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. J. A. Rossington, O. I. Brown, and A. Hoye, “Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome,” Open Heart, vol. 3, Article ID e000296, 2016. View at Publisher · View at Google Scholar
  41. D. J. Angiolillo, J. A. Jakubowski, J. L. Ferreiro et al., “Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease,” Journal of the American College of Cardiology, vol. 64, no. 10, pp. 1005–1014, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. E. T. Carreras, W. Hochholzer, A. L. Frelinger et al., “Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel: insights from the ELEVATE-TIMI 56 trial,” Thrombosis and Haemostasis, vol. 116, no. 1, pp. 69–77, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. J. W. Jukema, J. J. W. Verschuren, T. A. N. Ahmed, and P. H. A. Quax, “Restenosis after PCI. Part 1: pathophysiology and risk factors,” Nature Reviews Cardiology, vol. 9, no. 1, pp. 53–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Stettler, S. Wandel, S. Allemann et al., “Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis,” Lancet, vol. 370, no. 9591, pp. 937–948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. A. J. Kirtane, A. Gupta, S. Iyengar et al., “Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies,” Circulation, vol. 119, no. 25, pp. 3198–3206, 2009. View at Publisher · View at Google Scholar · View at Scopus